Jingjun Huang

1.3k total citations · 1 hit paper
36 papers, 916 citations indexed

About

Jingjun Huang is a scholar working on Hepatology, Pathology and Forensic Medicine and Epidemiology. According to data from OpenAlex, Jingjun Huang has authored 36 papers receiving a total of 916 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hepatology, 8 papers in Pathology and Forensic Medicine and 8 papers in Epidemiology. Recurrent topics in Jingjun Huang's work include Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cancer Mechanisms and Therapy (8 papers) and Liver Disease Diagnosis and Treatment (8 papers). Jingjun Huang is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (14 papers), Cancer Mechanisms and Therapy (8 papers) and Liver Disease Diagnosis and Treatment (8 papers). Jingjun Huang collaborates with scholars based in China, United States and Canada. Jingjun Huang's co-authors include Wensou Huang, Kangshun Zhu, Liteng Lin, Rodney J. Wigent, Yongjian Guo, Mingyue Cai, Joseph B. Schwartz, Licong Liang, Jingwen Zhou and Yong Wang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Radiology.

In The Last Decade

Jingjun Huang

33 papers receiving 907 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study

2022 117 citations Mingyue Cai, Wensou Huang et al. Frontiers in Immunology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jingjun Huang China	17	327	208	166	148	139	36	916
Xilin Du China	23	183 0.6×	511 2.5×	144 0.9×	167 1.1×	35 0.3×	58	1.5k
Ashutosh Barve United States	15	113 0.3×	295 1.4×	200 1.2×	147 1.0×	25 0.2×	26	910
Hongchuan Zhao China	14	146 0.4×	171 0.8×	99 0.6×	129 0.9×	8 0.1×	39	645
Yoshiyuki Yabe Japan	11	78 0.2×	270 1.3×	51 0.3×	184 1.2×	19 0.1×	18	638
Young Jun Kim South Korea	19	119 0.4×	514 2.5×	129 0.8×	72 0.5×	8 0.1×	46	957
Mingmei Liao China	13	41 0.1×	274 1.3×	43 0.3×	91 0.6×	45 0.3×	15	566
Elisa Herráez Spain	18	119 0.4×	386 1.9×	132 0.8×	490 3.3×	8 0.1×	43	993
Xiaofeng Zhang China	20	355 1.1×	362 1.7×	168 1.0×	453 3.1×	5 0.0×	44	1.2k
Fazong Wu China	17	207 0.6×	507 2.4×	98 0.6×	241 1.6×	5 0.0×	38	1.0k
Kaiwen Hu China	14	208 0.6×	260 1.3×	131 0.8×	186 1.3×	3 0.0×	78	892

Countries citing papers authored by Jingjun Huang

Since Specialization

Citations

This map shows the geographic impact of Jingjun Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jingjun Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jingjun Huang more than expected).

Fields of papers citing papers by Jingjun Huang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jingjun Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jingjun Huang. The network helps show where Jingjun Huang may publish in the future.

Co-authorship network of co-authors of Jingjun Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Jingjun Huang. A scholar is included among the top collaborators of Jingjun Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jingjun Huang. Jingjun Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Shuanggang, Lujun Shen, Boyang Chang, et al.. (2025). Development and validation of the NTAA prognostic model for BCLC stage B hepatocellular carcinoma undergoing transarterial chemoembolization: a retrospective multicenter cohort study. International Journal of Surgery. 111(12). 9411–9420.

Zhou, Jingwen, Jingjun Huang, Yongjian Guo, et al.. (2025). Sorafenib Combined with Tislelizumab and Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: A Phase II Study. ImmunoTargets and Therapy. Volume 14. 1187–1200.

Guo, Yongjian, Liteng Lin, Ye Chen, et al.. (2025). Donafenib combined with sintilimab for advanced hepatocellular carcinoma: a single arm phase II trial. BMC Cancer. 25(1). 205–205. 2 indexed citations

Huang, Jingjun, Wensou Huang, Licong Liang, et al.. (2025). Selective internal radiation therapy with yttrium-90 resin microspheres followed by lenvatinib plus PD-1 inhibitor for large or huge advanced-stage hepatocellular carcinoma: A retrospective cohort study from China.. Journal of Clinical Oncology. 43(4_suppl). 581–581. 1 indexed citations

Li, Rui, Zhile Liu, Wensou Huang, et al.. (2024). Microbial-derived Urolithin A Targets GLS1 to Inhibit Glutaminolysis and Attenuate Cirrhotic Portal Hypertension. Cellular and Molecular Gastroenterology and Hepatology. 18(4). 101379–101379. 2 indexed citations

Xie, Xiaodong, Xiaowei Jin, Jingjun Huang, et al.. (2023). High resveratrol-loaded microcapsules with trehalose and OSA starch as the wall materials: Fabrication, characterization, and evaluation. International Journal of Biological Macromolecules. 242(Pt 2). 124825–124825. 13 indexed citations

Liu, Mingyu, Lulu Xie, Yuying Zhang, et al.. (2023). Inhibition of CEMIP potentiates the effect of sorafenib on metastatic hepatocellular carcinoma by reducing the stiffness of lung metastases. Cell Death and Disease. 14(1). 25–25. 18 indexed citations

Chen, Ye, Qianbing Zhang, Xiaobin Wang, et al.. (2023). HBV suppresses macrophage immune responses by impairing the TCA cycle through the induction of CS/PDHC hyperacetylation. Hepatology Communications. 7(11). 11 indexed citations

Wang, Xiaobin, Qiaoyun Zhang, Jingwen Zhou, et al.. (2023). T cell-mediated targeted delivery of tadalafil regulates immunosuppression and polyamine metabolism to overcome immune checkpoint blockade resistance in hepatocellular carcinoma. Journal for ImmunoTherapy of Cancer. 11(2). e006493–e006493. 17 indexed citations

10.

Cai, Mingyue, Wensou Huang, Jingjun Huang, et al.. (2022). Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study. Frontiers in Immunology. 13. 117 indexed citations breakdown →

11.

Chen, Ye, Mingyu Liu, Jingjun Huang, et al.. (2021). Sublethal heat stress-induced O-GlcNAcylation coordinates the Warburg effect to promote hepatocellular carcinoma recurrence and metastasis after thermal ablation. Cancer Letters. 518. 23–34. 42 indexed citations

12.

Huang, Jingjun, Wensou Huang, Meixiao Zhan, et al.. (2021). Drug-Eluting Bead Transarterial Chemoembolization Combined with FOLFOX-Based Hepatic Arterial Infusion Chemotherapy for Large or Huge Hepatocellular Carcinoma. Journal of Hepatocellular Carcinoma. Volume 8. 1445–1458. 27 indexed citations

13.

Cai, Mingyue, Bo Li, Liteng Lin, et al.. (2020). A reduction and pH dual-sensitive nanodrug for targeted theranostics in hepatocellular carcinoma. Biomaterials Science. 8(12). 3485–3499. 31 indexed citations

14.

Lin, Liteng, Rui Li, Jingjun Huang, et al.. (2020). Nanodrug with ROS and pH Dual‐Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation. Advanced Science. 7(7). 1903138–1903138. 80 indexed citations

15.

Guo, Yongjian, Liteng Lin, Jingjun Huang, et al.. (2019). LncRNA DLEU2 aggravates the progression of hepatocellular carcinoma through binding to EZH2. Biomedicine & Pharmacotherapy. 118. 109272–109272. 42 indexed citations

16.

Lin, Liteng, Rui Li, Mingyue Cai, et al.. (2018). Andrographolide Ameliorates Liver Fibrosis in Mice: Involvement of TLR4/NF‐κB and TGF‐β1/Smad2 Signaling Pathways. Oxidative Medicine and Cellular Longevity. 2018(1). 7808656–7808656. 48 indexed citations

17.

Meng, Xiaochun, Binghui Chen, Jingjun Huang, et al.. (2018). Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World Journal of Gastroenterology. 24(4). 484–493. 8 indexed citations

18.

Cai, Mingyue, Wensou Huang, Jingjun Huang, et al.. (2016). Delayed bronchobiliary fistula following radiofrequency ablation in a patient with hepatocellular carcinoma: A case report and lesson regarding treatment. Oncology Letters. 11(5). 3213–3217. 11 indexed citations

19.

Huang, Jingjun, Rodney J. Wigent, & Joseph B. Schwartz. (2007). Drug–polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend. Journal of Pharmaceutical Sciences. 97(1). 251–262. 102 indexed citations

20.

Huang, Jingjun, Rodney J. Wigent, & Joseph B. Schwartz. (2006). Nifedipine Molecular Dispersion in Microparticles of Ammonio Methacrylate Copolymer and Ethylcellulose Binary Blends for Controlled Drug Delivery: Effect of Matrix Composition. Drug Development and Industrial Pharmacy. 32(10). 1185–1197. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact